Monte Rosa Therapeutics Ownership 2024 | Who Owns Monte Rosa Therapeutics Now?
Institutional Ownership
8.23%
Insider Ownership
0.71%
Retail Ownership
91.06%
Institutional Holders
21.00
Monte Rosa Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NEA MANAGEMENT COMPANY, LLC | 12.79% | 2.16% | 7,692,298 | - | - | 28,769,195 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 9.94% | 0.00% | 5,977,587 | 880,800 | 17.28% | 22,357,000 | Jun 30, 2024 |
| FMR LLC | 8.47% | 0.00% | 5,094,974 | -245,828 | -4.60% | 19,055,203 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 8.17% | 0.23% | 4,916,095 | - | - | 18,386,195 | Jun 30, 2024 |
| AVORO CAPITAL ADVISORS LLC | 7.54% | 0.23% | 4,535,000 | - | - | 16,960,900 | Jun 30, 2024 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.42% | 0.37% | 2,659,000 | 2,659,000 | 100.00% | 9,944,660 | Jun 30, 2024 |
| VANGUARD GROUP INC | 4.23% | 0.00% | 2,547,075 | 911,246 | 55.71% | 9,526,061 | Jun 30, 2024 |
| BLACKROCK INC. | 3.92% | 0.00% | 2,360,093 | 53,084 | 2.30% | 8,826,748 | Jun 30, 2024 |
| AISLING CAPITAL MANAGEMENT LP | 2.45% | 2.38% | 1,472,331 | - | - | 5,506,518 | Jun 30, 2024 |
| ALPHABET INC. | 2.43% | 0.28% | 1,464,015 | - | - | 5,475,416 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 1.48% | 0.25% | 890,000 | 890,000 | 100.00% | 3,328,600 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.41% | 0.00% | 847,442 | 111,909 | 15.21% | 3,169,853 | Jun 30, 2024 |
| STATE STREET CORP | 1.06% | 0.00% | 636,084 | 20,833 | 3.39% | 2,378,954,000 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.62% | 0.19% | 375,000 | 375,000 | 100.00% | 1,402,500 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.52% | 0.00% | 311,800 | 61,218 | 24.43% | 1,166,132 | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | 0.51% | 0.01% | 307,319 | 42,041 | 15.85% | 1,149,000 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.49% | 0.00% | 294,196 | 3,742 | 1.29% | 1,100,293,000 | Jun 30, 2024 |
| CASDIN CAPITAL, LLC | 0.43% | 0.07% | 261,014 | -249,868 | -48.91% | 976,192 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.42% | 0.00% | 254,714 | 132,614 | 108.61% | 952,630 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.32% | 0.00% | 193,696 | 528 | 0.27% | 724,423 | Jun 30, 2024 |
Monte Rosa Therapeutics's largest institutional shareholder is NEA MANAGEMENT COMPANY, LLC, holding 12.79% of the company's total share outstanding, currently valued at $28.77M. The top 10 institutional shareholders own together 64.36% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AISLING CAPITAL MANAGEMENT LP | 2.45% | 2.38% | 1,472,331 | - | - | 5,506,518 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 12.79% | 2.16% | 7,692,298 | - | - | 28,769,195 | Jun 30, 2024 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.42% | 0.37% | 2,659,000 | 2,659,000 | 100.00% | 9,944,660 | Jun 30, 2024 |
| ALPHABET INC. | 2.43% | 0.28% | 1,464,015 | - | - | 5,475,416 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 1.48% | 0.25% | 890,000 | 890,000 | 100.00% | 3,328,600 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 8.17% | 0.23% | 4,916,095 | - | - | 18,386,195 | Jun 30, 2024 |
| AVORO CAPITAL ADVISORS LLC | 7.54% | 0.23% | 4,535,000 | - | - | 16,960,900 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.62% | 0.19% | 375,000 | 375,000 | 100.00% | 1,402,500 | Jun 30, 2024 |
| LONG CORRIDOR ASSET MANAGEMENT LTD | 0.07% | 0.14% | 40,000 | - | - | 149,600 | Jun 30, 2024 |
| CASDIN CAPITAL, LLC | 0.43% | 0.07% | 261,014 | -249,868 | -48.91% | 976,192 | Jun 30, 2024 |
| CASTLEVIEW PARTNERS, LLC | 0.03% | 0.04% | 18,950 | 18,950 | 100.00% | 70,873 | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | 0.07% | 0.03% | 41,917 | -476 | -1.12% | 156,770 | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | 0.51% | 0.01% | 307,319 | 42,041 | 15.85% | 1,149,000 | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.04% | 0.01% | 25,346 | 25,346 | 100.00% | 95,000 | Jun 30, 2024 |
| EXCHANGE TRADED CONCEPTS, LLC | 0.06% | 0.00% | 35,686 | -11,101 | -23.73% | 133,466 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 9.94% | 0.00% | 5,977,587 | 880,800 | 17.28% | 22,357,000 | Jun 30, 2024 |
| MEEDER ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,050 | 10,050 | 100.00% | 37,587 | Jun 30, 2024 |
| SARASIN & PARTNERS LLP | 0.11% | 0.00% | 65,081 | - | - | 243,403 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.42% | 0.00% | 254,714 | 132,614 | 108.61% | 952,630 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.03% | 0.00% | 16,338 | -560 | -3.31% | 61,104 | Jun 30, 2024 |
The largest Monte Rosa Therapeutics shareholder by % of total assets is AISLING CAPITAL MANAGEMENT LP. The company owns 1.47M shares of Monte Rosa Therapeutics (GLUE), representing 2.38% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.42% | 0.37% | 2,659,000 | 2,659,000 | 100.00% | 9,944,660 | Jun 30, 2024 |
| VANGUARD GROUP INC | 4.23% | 0.00% | 2,547,075 | 911,246 | 55.71% | 9,526,061 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 1.48% | 0.25% | 890,000 | 890,000 | 100.00% | 3,328,600 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 9.94% | 0.00% | 5,977,587 | 880,800 | 17.28% | 22,357,000 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.62% | 0.19% | 375,000 | 375,000 | 100.00% | 1,402,500 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.42% | 0.00% | 254,714 | 132,614 | 108.61% | 952,630 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.41% | 0.00% | 847,442 | 111,909 | 15.21% | 3,169,853 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.26% | 0.00% | 153,758 | 81,083 | 111.57% | 575,055 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.15% | 0.00% | 92,349 | 76,585 | 485.82% | 345,386 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.52% | 0.00% | 311,800 | 61,218 | 24.43% | 1,166,132 | Jun 30, 2024 |
| BLACKROCK INC. | 3.92% | 0.00% | 2,360,093 | 53,084 | 2.30% | 8,826,748 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.28% | 0.00% | 166,671 | 46,024 | 38.15% | 623,350 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.16% | 0.00% | 98,557 | 43,009 | 77.43% | 366,000 | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | 0.51% | 0.01% | 307,319 | 42,041 | 15.85% | 1,149,000 | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.04% | 0.01% | 25,346 | 25,346 | 100.00% | 95,000 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 0.04% | 0.00% | 23,422 | 23,422 | 100.00% | 87,598 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.04% | 0.00% | 22,665 | 22,665 | 100.00% | 84,767 | Jun 30, 2024 |
| STATE STREET CORP | 1.06% | 0.00% | 636,084 | 20,833 | 3.39% | 2,378,954,000 | Jun 30, 2024 |
| CASTLEVIEW PARTNERS, LLC | 0.03% | 0.04% | 18,950 | 18,950 | 100.00% | 70,873 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.03% | 0.00% | 16,566 | 16,566 | 100.00% | 61,957 | Jun 30, 2024 |
As of Jun 30 2024, Monte Rosa Therapeutics's largest institutional buyer is SUVRETTA CAPITAL MANAGEMENT, LLC. The company purchased 2.66M stocks of GLUE, valued at $9.94M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CASDIN CAPITAL, LLC | 0.43% | 0.07% | 261,014 | -249,868 | -48.91% | 976,192 | Jun 30, 2024 |
| FMR LLC | 8.47% | 0.00% | 5,094,974 | -245,828 | -4.60% | 19,055,203 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.03% | - | 20,928 | -129,097 | -86.05% | 78,271 | Jun 30, 2024 |
| UBS GROUP AG | 0.04% | - | 23,294 | -17,879 | -43.42% | 87,120 | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -15,893 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -15,246 | -100.00% | - | Jun 30, 2024 |
| PDT PARTNERS, LLC | - | - | - | -13,955 | -100.00% | - | Jun 30, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | - | - | - | -11,946 | -100.00% | - | Jun 30, 2024 |
| METLIFE INVESTMENT MANAGEMENT, LLC | - | - | - | -11,419 | -100.00% | - | Jun 30, 2024 |
| EXCHANGE TRADED CONCEPTS, LLC | 0.06% | 0.00% | 35,686 | -11,101 | -23.73% | 133,466 | Jun 30, 2024 |
| BARCLAYS PLC | 0.02% | - | 11,009 | -10,739 | -49.38% | 41,000 | Jun 30, 2024 |
| STATE OF WISCONSIN INVESTMENT BOARD | 0.08% | 0.00% | 45,500 | -7,300 | -13.83% | 170,170 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 0.02% | - | 10,860 | -2,528 | -18.88% | 40,616 | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -1,820 | -100.00% | - | Jun 30, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0.00% | - | 2,208 | -903 | -29.03% | 8,258 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.03% | 0.00% | 16,338 | -560 | -3.31% | 61,104 | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | 0.07% | 0.03% | 41,917 | -476 | -1.12% | 156,770 | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.17% | 0.00% | 102,709 | -378 | -0.37% | 384,132 | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -6 | -100.00% | - | Jun 30, 2024 |
| AISLING CAPITAL MANAGEMENT LP | 2.45% | 2.38% | 1,472,331 | - | - | 5,506,518 | Jun 30, 2024 |
As of Jun 30 2024, Monte Rosa Therapeutics's biggest institutional seller is CASDIN CAPITAL, LLC. The company sold -0.25M shares of GLUE, valued at $976.19K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.42% | 0.37% | 2,659,000 | 2,659,000 | 100.00% | 9,944,660 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 1.48% | 0.25% | 890,000 | 890,000 | 100.00% | 3,328,600 | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.04% | 0.01% | 25,346 | 25,346 | 100.00% | 95,000 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 0.04% | 0.00% | 23,422 | 23,422 | 100.00% | 87,598 | Jun 30, 2024 |
| CASTLEVIEW PARTNERS, LLC | 0.03% | 0.04% | 18,950 | 18,950 | 100.00% | 70,873 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.03% | 0.00% | 16,566 | 16,566 | 100.00% | 61,957 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.03% | 0.00% | 16,394 | 16,394 | 100.00% | 61,314 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.03% | 0.00% | 16,270 | 16,270 | 100.00% | 60,850 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 0.03% | - | 15,600 | 15,600 | 100.00% | 58,344 | Jun 30, 2024 |
| MEEDER ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,050 | 10,050 | 100.00% | 37,587 | Jun 30, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | 0.00% | - | 2,631 | 2,631 | 100.00% | 9,839 | Jun 30, 2024 |
| PNC FINANCIAL SERVICES GROUP, INC. | - | - | 28 | 28 | 100.00% | 105 | Jun 30, 2024 |
Monte Rosa Therapeutics's largest new institutional shareholder by number of shares is SUVRETTA CAPITAL MANAGEMENT, LLC, purchased 2.66M shares, valued at $9.94M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ENTRYPOINT CAPITAL, LLC | - | - | - | -15,893 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -15,246 | -100.00% | - | Jun 30, 2024 |
| PDT PARTNERS, LLC | - | - | - | -13,955 | -100.00% | - | Jun 30, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | - | - | - | -11,946 | -100.00% | - | Jun 30, 2024 |
| METLIFE INVESTMENT MANAGEMENT, LLC | - | - | - | -11,419 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -1,820 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -6 | -100.00% | - | Jun 30, 2024 |
Monte Rosa Therapeutics's largest sold out institutional shareholder by shares sold is ENTRYPOINT CAPITAL, LLC, sold -15.89K shares, valued at -, as of undefined.
Monte Rosa Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| DSS AMERICAFIRST QUANTITATIVE FUNDS | 2.02% | 46,000 | 46,000 | - | Dec 29, 2023 |
| T. Rowe Price New Horizons Fund, Inc. | 0.59% | 2,941,087 | 181,506 | 6.58% | Mar 31, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.25% | 819,434 | -124,220 | -13.16% | Mar 31, 2024 |
| CORNERCAP GROUP OF FUNDS /VA/ | 0.19% | 13,615 | 13,615 | - | Sep 30, 2022 |
| BlackRock Health Sciences Trust | 0.11% | 28,575 | - | - | Mar 31, 2024 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.11% | 389,927 | - | - | Mar 31, 2024 |
| PRUDENTIAL SECTOR FUNDS, INC. | 0.11% | 218,779 | - | - | Feb 29, 2024 |
| Voya VARIABLE PRODUCTS TRUST | 0.10% | 36,189 | - | - | Mar 31, 2024 |
| BlackRock Health Sciences Trust II | 0.10% | 266,168 | - | - | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.07% | 632,258 | -435,700 | -40.80% | Jan 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.05% | 28,328 | - | - | Mar 31, 2024 |
| Vericimetry Funds | 0.05% | 4,620 | - | - | Mar 31, 2024 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.04% | 142,500 | 63,300 | 79.92% | Mar 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.04% | 1,109,991 | -171,461 | -13.38% | Feb 29, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.03% | 51,821 | - | - | Mar 31, 2024 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.03% | 211,893 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.03% | 1,736,205 | - | - | Feb 29, 2024 |
| T. Rowe Price Equity Funds, Inc. | 0.02% | 209,491 | - | - | Mar 31, 2024 |
| Voya EQUITY TRUST | 0.01% | 21,177 | - | - | Feb 29, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.01% | 37,374 | 11,002 | 41.72% | Feb 29, 2024 |
| FIDELITY SECURITIES FUND | 0.01% | 852,355 | - | - | Jan 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 55,657 | - | - | Mar 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.01% | 95,973 | - | - | Jan 31, 2024 |
| Nushares ETF Trust | 0.01% | 53,833 | - | - | Jan 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 4,311 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND III | 0.01% | 54,800 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,293,042 | -407,579 | -23.97% | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 419,477 | - | - | Feb 29, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 83,209 | - | - | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 308,236 | 32,864 | 11.93% | Feb 29, 2024 |
| ETF Series Solutions | 0.00% | 27,445 | 4,397 | 19.08% | Feb 29, 2024 |
| T. Rowe Price Spectrum Funds II, Inc. | 0.00% | 17,265 | - | - | Feb 29, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 21,860 | - | - | Jan 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 213 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 27,915 | -1,575 | -5.34% | Mar 31, 2024 |
| Managed Portfolio Series | 0.00% | 19,236 | 5,621 | 41.29% | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 2,241 | - | - | Mar 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 15,017 | 555 | 3.84% | Mar 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 7,996 | - | - | Mar 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 109,431 | -33,035 | -23.19% | Feb 29, 2024 |
| Virtus Investment Trust | 0.00% | 12,638 | - | - | Mar 28, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 10,558 | -1,907 | -15.30% | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,484 | - | - | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 166,981 | 5,611 | 3.48% | Feb 29, 2024 |
| Global X Funds | 0.00% | 11,946 | - | - | Jan 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 30,168 | 7,042 | 30.45% | Feb 29, 2024 |
| BlackRock ETF Trust | 0.00% | 230 | - | - | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 579 | - | - | Mar 31, 2024 |
| HC CAPITAL TRUST | 0.00% | 5,968 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 25,234 | -1,090 | -4.14% | Mar 28, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 10,200 | - | - | Mar 31, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 14,609 | - | - | Mar 28, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 1,481 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 97,871 | -4,007 | -3.93% | Mar 31, 2024 |
| Dimensional ETF Trust | 0.00% | 30,226 | 26,756 | 771.07% | Jan 31, 2024 |
| iSHARES TRUST | 0.00% | 1,123,710 | -65,399 | -5.50% | Mar 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 278 | - | - | Dec 31, 2023 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 133,186 | 15,583 | 13.25% | Feb 29, 2024 |
| VALIC Co I | 0.00% | 11,705 | -47 | -0.40% | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,100 | - | - | Mar 28, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 2,453 | - | - | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 4,852 | - | - | Mar 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 138 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 3,737 | -794 | -17.52% | Jan 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 153 | - | - | Feb 29, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 25,090 | 8,023 | 47.01% | Jan 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 72,541 | -11,581 | -13.77% | Jan 31, 2024 |
| ProFunds | 0.00% | 241 | -14 | -5.49% | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 4,227 | 808 | 23.63% | Jan 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 39,233 | -1,456 | -3.58% | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 4,470 | -2,632 | -37.06% | Feb 29, 2024 |
| Brighthouse Funds Trust II | 0.00% | 14,746 | -6,738 | -31.36% | Mar 31, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 18 | - | - | Dec 31, 2023 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 14,704 | - | - | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,250 | - | - | Feb 29, 2024 |
| Franklin Alternative Strategies Funds | 0.00% | 6,745 | - | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 27,441 | - | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 11,162 | 4,149 | 59.16% | Dec 31, 2023 |
| SUNAMERICA SERIES TRUST | 0.00% | 3,455 | -14 | -0.40% | Jan 31, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 536 | - | - | Feb 29, 2024 |
| J.P. Morgan Exchange-Traded Fund Trust | 0.00% | 3,674 | - | - | Jan 31, 2024 |
| T. Rowe Price Multi-Strategy Total Return Fund, Inc. | 0.00% | 1,189 | - | - | Jan 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 22,942 | -457 | -1.95% | Mar 31, 2024 |
| TRANSAMERICA SERIES TRUST | 0.00% | 5,200 | - | - | Mar 31, 2024 |
| SPDR INDEX SHARES FUNDS | 0.00% | 986 | - | - | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 11,695 | -389 | -3.22% | Mar 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 852 | - | - | Jan 31, 2024 |
| Bridge Builder Trust | 0.00% | 11,989 | - | - | Mar 31, 2024 |
| John Hancock Funds II | 0.00% | 35,064 | - | - | Feb 29, 2024 |
| GOLDMAN SACHS TRUST | 0.00% | 5,700 | - | - | Mar 31, 2024 |
| COLUMBIA FUNDS SERIES TRUST I | 0.00% | 6,154 | - | - | Feb 29, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 4,328 | - | - | Mar 31, 2024 |
| Advisors' Inner Circle Fund III | 0.00% | 95 | -5 | -5.00% | Jan 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 3,846 | -641 | -14.29% | Jan 31, 2024 |
| BLACKROCK FUNDS | 0.00% | 3,256 | - | - | Jan 31, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 8,900 | - | - | Feb 29, 2024 |
Monte Rosa Therapeutics's largest mutual fund holder by % of total assets is "DSS AMERICAFIRST QUANTITATIVE FUNDS", owning 46.00K shares, compromising 2.02% of its total assets.
Monte Rosa Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 21 | -70.42% |
| 31 Mar, 24 | 71 | -10.13% |
| 31 Dec, 23 | 79 | 5.33% |
| 30 Sep, 23 | 75 | 7.14% |
| 30 Jun, 23 | 70 | -1.41% |
| 31 Mar, 23 | 71 | 2.90% |
| 31 Dec, 22 | 69 | -1.43% |
| 30 Sep, 22 | 70 | 22.81% |
| 30 Jun, 22 | 57 | 7.55% |
| 31 Mar, 22 | 53 | - |
| 31 Dec, 21 | 53 | -3.64% |
| 30 Sep, 21 | 55 | 14.58% |
| 30 Jun, 21 | 48 | - |
As of 30 Jun 24, 21 institutions are holding Monte Rosa Therapeutics's shares, representing a decrease of -70.42% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 4,952,408 | -87.59% |
| 31 Mar, 24 | 39,892,663 | -0.52% |
| 31 Dec, 23 | 40,102,427 | -4.61% |
| 30 Sep, 23 | 42,042,262 | 5.78% |
| 30 Jun, 23 | 39,746,136 | -0.06% |
| 31 Mar, 23 | 39,769,102 | -3.76% |
| 31 Dec, 22 | 41,324,513 | 2.66% |
| 30 Sep, 22 | 40,254,389 | 3.81% |
| 30 Jun, 22 | 38,778,723 | -3.08% |
| 31 Mar, 22 | 40,010,499 | 10.10% |
| 31 Dec, 21 | 36,340,058 | 4.15% |
| 30 Sep, 21 | 34,892,123 | 8.71% |
| 30 Jun, 21 | 32,095,195 | - |
Monte Rosa Therapeutics (GLUE) has 4.95M shares outstanding as of 30 Jun 24, down -87.59% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 8.23% | 0.14% |
| 31 Mar, 24 | 77.62% | 1.20% |
| 31 Dec, 23 | 80.50% | 1.11% |
| 30 Sep, 23 | 85.05% | 1.31% |
| 30 Jun, 23 | 80.54% | 1.24% |
| 31 Mar, 23 | 80.59% | 1.05% |
| 31 Dec, 22 | 87.50% | 1.18% |
| 30 Sep, 22 | 86.14% | 1.25% |
| 30 Jun, 22 | 83.09% | 1.13% |
| 31 Mar, 22 | 85.87% | 1.38% |
| 31 Dec, 21 | 79.02% | 1.37% |
| 30 Sep, 21 | 75.87% | 1.56% |
| 30 Jun, 21 | 69.79% | - |
As of 30 Jun 24, Monte Rosa Therapeutics is held by 8.23% institutional shareholders, representing a 0.14% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 15 | -48.28% |
| 31 Mar, 24 | 29 | 3.57% |
| 31 Dec, 23 | 28 | -30.00% |
| 30 Sep, 23 | 40 | -4.76% |
| 30 Jun, 23 | 42 | 35.48% |
| 31 Mar, 23 | 31 | -3.13% |
| 31 Dec, 22 | 32 | -13.51% |
| 30 Sep, 22 | 37 | 19.35% |
| 30 Jun, 22 | 31 | -13.89% |
| 31 Mar, 22 | 36 | 9.09% |
| 31 Dec, 21 | 33 | - |
| 30 Sep, 21 | 33 | -31.25% |
| 30 Jun, 21 | 48 | - |
15 institutional shareholders have increased their position in GLUE stock as of 30 Jun 24 compared to 29 in the previous quarter (a -48.28% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 1 | -95.65% |
| 31 Mar, 24 | 23 | -11.54% |
| 31 Dec, 23 | 26 | 52.94% |
| 30 Sep, 23 | 17 | 54.55% |
| 30 Jun, 23 | 11 | -47.62% |
| 31 Mar, 23 | 21 | 16.67% |
| 31 Dec, 22 | 18 | 20.00% |
| 30 Sep, 22 | 15 | - |
| 30 Jun, 22 | 15 | 114.29% |
| 31 Mar, 22 | 7 | -30.00% |
| 31 Dec, 21 | 10 | -23.08% |
| 30 Sep, 21 | 13 | - |
| 30 Jun, 21 | - | - |
1 institutional shareholders have reduced their position in GLUE stock as of 30 Jun 24 compared to 23 in the previous quarter (a -95.65% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 21 | -70.42% | 4,952,408 | -87.59% | 8.23% | 0.14% | 15 | -48.28% | 1 | -95.65% |
| 31 Mar, 24 | 71 | -10.13% | 39,892,663 | -0.52% | 77.62% | 1.20% | 29 | 3.57% | 23 | -11.54% |
| 31 Dec, 23 | 79 | 5.33% | 40,102,427 | -4.61% | 80.50% | 1.11% | 28 | -30.00% | 26 | 52.94% |
| 30 Sep, 23 | 75 | 7.14% | 42,042,262 | 5.78% | 85.05% | 1.31% | 40 | -4.76% | 17 | 54.55% |
| 30 Jun, 23 | 70 | -1.41% | 39,746,136 | -0.06% | 80.54% | 1.24% | 42 | 35.48% | 11 | -47.62% |
| 31 Mar, 23 | 71 | 2.90% | 39,769,102 | -3.76% | 80.59% | 1.05% | 31 | -3.13% | 21 | 16.67% |
| 31 Dec, 22 | 69 | -1.43% | 41,324,513 | 2.66% | 87.50% | 1.18% | 32 | -13.51% | 18 | 20.00% |
| 30 Sep, 22 | 70 | 22.81% | 40,254,389 | 3.81% | 86.14% | 1.25% | 37 | 19.35% | 15 | - |
| 30 Jun, 22 | 57 | 7.55% | 38,778,723 | -3.08% | 83.09% | 1.13% | 31 | -13.89% | 15 | 114.29% |
| 31 Mar, 22 | 53 | - | 40,010,499 | 10.10% | 85.87% | 1.38% | 36 | 9.09% | 7 | -30.00% |
| 31 Dec, 21 | 53 | -3.64% | 36,340,058 | 4.15% | 79.02% | 1.37% | 33 | - | 10 | -23.08% |
| 30 Sep, 21 | 55 | 14.58% | 34,892,123 | 8.71% | 75.87% | 1.56% | 33 | -31.25% | 13 | - |
| 30 Jun, 21 | 48 | - | 32,095,195 | - | 69.79% | - | 48 | - | - | - |
Monte Rosa Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Monte Rosa Therapeutics's stock was made by Dunn Edmund on Jul 09 2024, selling 1,610 shares at $3.83 per share (valued at $6.17K).
Monte Rosa Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 9 | 11 | 81.82% |
| Q1 2024 | 7 | - | - |
| Q3 2023 | 1 | 4 | 25.00% |
| Q2 2023 | 6 | - | - |
| Q1 2023 | 9 | - | - |
| Q4 2022 | 2 | - | - |
| Q2 2022 | 8 | - | - |
| Q1 2022 | 8 | 2 | 400.00% |
| Q4 2021 | - | 2 | - |
| Q2 2021 | 78 | 60 | 130.00% |
| Q1 2021 | 3 | - | - |
9 total buy trades, and 11 total sell trades (buy/sell ratio of 0.82%) were made by Monte Rosa Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | 1 | - |
| Q1 2024 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | - | - |
| Q4 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | - | - |
| Q2 2021 | 16 | - | - |
| Q1 2021 | - | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 1 open market sell trades of Monte Rosa Therapeutics's stocks.
Monte Rosa Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| SANA | Sana Biotechnology, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| IKNA | Ikena Oncology, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| STOK | Stoke Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| GBIO | Generation Bio Co. |
| LYEL | Lyell Immunopharma, Inc. |
| DSGN | Design Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| NKTX | Nkarta, Inc. |
| STTK | Shattuck Labs, Inc. |
GLUE Ownership FAQ
Who Owns Monte Rosa Therapeutics?
Monte Rosa Therapeutics is owned by institutional shareholders (8.23%), insiders (0.71%), and public (91.06%). The largest institutional shareholder of Monte Rosa Therapeutics is NEA MANAGEMENT COMPANY, LLC (12.79% of total shares) and the top mutual fund owner is DSS AMERICAFIRST QUANTITATIVE FUNDS (2.02% of total shares).
Who are the major institutional shareholders of Monte Rosa Therapeutics?
Monte Rosa Therapeutics's major institutional shareholders are NEA MANAGEMENT COMPANY, LLC, PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, BAKER BROS. ADVISORS LP, and AVORO CAPITAL ADVISORS LLC. The top five shareholders own together 46.90% of the company's share outstanding.
How many Monte Rosa Therapeutics shareholders are there?
As of Jun 2024, there are 21 institutional shareholders of Monte Rosa Therapeutics.
What percentage of Monte Rosa Therapeutics is owned by NEA MANAGEMENT COMPANY, LLC?
NEA MANAGEMENT COMPANY, LLC owns 7.69M shares of Monte Rosa Therapeutics, representing 12.79% of the company's total shares outstanding, valued at $28.77M (as of Jun 2024).
What percentage of Monte Rosa Therapeutics is owned by PRICE T ROWE ASSOCIATES INC /MD/?
As of Jun 2024, PRICE T ROWE ASSOCIATES INC /MD/ holds 5.98M shares of Monte Rosa Therapeutics (GLUE), compromising 9.94% of the company, valued at $22.36M.
What percentage of Monte Rosa Therapeutics is owned by FMR LLC?
FMR LLC is the third largest holder of Monte Rosa Therapeutics. The company owns 5.09M of the company's shares outstanding (worth $19.06M).